| 2023 | Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE |
| 2023 | Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41 | BREAST CANCER RESEARCH AND TREATMENT |
| 2023 | Fusobacterium nucleatum induces a tumor microenvironment with diminished adaptive immunity against colorectal cancers
| FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY |
| 2022 | Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev | JOURNAL OF CLINICAL ONCOLOGY |
| 2021 | Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer
| SCIENTIFIC REPORTS |
| 2021 | Genomic landscape of extraordinary responses in metastatic breast cancer
| COMMUNICATIONS BIOLOGY |
| 2021 | Dynamic changes in circulating PD-1(+)CD8(+)T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
| 2020 | Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
| BRITISH JOURNAL OF CANCER |
| 2020 | An Improved, Assay Platform Agnostic, Absolute Single Sample Breast Cancer Subtype Classifier
| CANCERS |
| 2020 | Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
| JNCI CANCER SPECTRUM |
| 2020 | Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma
| ISCIENCE |
| 2020 | Echocardiographic parameters determining cardiovascular outcomes in patients after acute ischemic stroke | INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING |
| 2020 | Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer
| SCIENTIFIC REPORTS |
| 2020 | Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer
| EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2020 | Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
| BMC CANCER |
| 2020 | Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial | JAMA ONCOLOGY |
| 2020 | NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+
| JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy | INTERNATIONAL JOURNAL OF CANCER |
| 2019 | PI3K/AKT/β-Catenin Signaling Regulates Vestigial-Like 1 Which Predicts Poor Prognosis and Enhances Malignant Phenotype in Gastric Cancer
| CANCERS |
| 2019 | Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE |
| 2019 | A therapeutic strategy for chemotherapy-resistant gastric cancer via destabilization of both β-catenin and ras
| CANCERS |
| 2019 | Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial | LANCET ONCOLOGY |
| 2018 | Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancer | British Journal of Cancer |
| 2018 | Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations
| PLoS One |
| 2018 | Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab
| Pharmacogenetics and Genomics |
| 2018 | 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology
| Breast Cancer Research and Treatment |
| 2018 | Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology) | BRITISH JOURNAL OF CANCER |
| 2018 | Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation | LUNG CANCER |
| 2018 | Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth
| GENOME RESEARCH |
| 2018 | Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells with Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT | GASTROENTEROLOGY |
| 2018 | Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information | ANNALS OF ONCOLOGY |
| 2018 | AIRVF: a filtering toolbox for precise variant calling in Ion Torrent sequencing | BIOINFORMATICS |
| 2017 | Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial
| JAMA ONCOLOGY |
| 2017 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research | ADVANCES IN ANATOMIC PATHOLOGY |
| 2017 | The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40 | ANNALS OF SURGICAL ONCOLOGY |
| 2017 | 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE |
| 2017 | Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
| ONCOTARGET |
| 2017 | Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma | ANNALS OF ONCOLOGY |
| 2017 | Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
| ONCOTARGET |
| 2017 | Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2016 | Prognostic Tests for Estrogen Receptor-Positive Breast Cancer: Need for Global Consideration and Further Evolution | JAMA ONCOLOGY |
| 2016 | Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial
| JAMA ONCOLOGY |
| 2016 | Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative
| ONCOTARGET |
| 2016 | Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy
| ONCOGENESIS |
| 2016 | CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2015 | Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
| ONCOTARGET |
| 2015 | Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2015 | Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
| MOLECULAR CANCER THERAPEUTICS |
| 2015 | Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial | LANCET ONCOLOGY |
| 2015 | Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial | JOURNAL OF CLINICAL ONCOLOGY |
http://orcid.org/0000-0001-9688-6480
(34977365100)
